FPT Digital Retail Joint Stock Company (FRT) Q1 2023 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2023 earnings summary
3 Nov, 2026Executive summary
Q1 2023 net revenue was VND 7.753tn and consolidated net profit was VND 2.070bn; profit attributable to parent shareholders was a VND 5.074bn loss.
Operating profit fell to VND 1.968bn from VND 202.556bn in Q1 2022, while financial expenses and selling expenses increased.
Financial highlights
Net revenue was VND 7.753tn versus VND 7.786tn in Q1 2022; gross profit was VND 1.186tn versus VND 1.233tn.
Cost of sales was VND 6.566tn versus VND 6.553tn; selling expenses rose to VND 913.156bn from VND 732.370bn.
Financial income was VND 16.544bn versus VND 50.469bn; financial expenses were VND 86.376bn versus VND 54.657bn, including interest expense of VND 85.393bn.
Consolidated net profit was VND 2.070bn versus VND 169.354bn; parent-attributable result was a VND 5.074bn loss versus VND 164.587bn profit.
Segment performance
Operations comprise informatics equipment, mobile phones, components and related accessories, and pharmaceutical business; no segment-level financial results are stated.
FPT Long Chau Pharma Joint Stock Company is listed as 88.50%-owned, with pharmaceutical business as its principal activity.
Latest events from FPT Digital Retail Joint Stock Company
- Revenue grew, but H1 swung to operating and net losses.FRT
Q2 2023 - Revenue grew, but 9M 2023 ended in a VND 225.704bn net loss.FRT
Q3 2023 - Revenue increased, but FY2023 ended with a VND 329.2bn net loss and heavy operating cash outflow.FRT
Q4 2023 - Gross profit and operating cash flow improved as revenue fell and losses narrowed.FRT
Q1 2024 - 9M revenue rose and earnings returned to profit, with operating cash flow at VND 1.74T.FRT
Q3 2024 - H1 revenue advanced, earnings returned to profit, and operating cash flow strengthened.FRT
Q2 2024 - FY2024 returned to profit despite lower revenue, with year-end cash rising to VND 1.170tn.FRT
Q4 2024 - Q1 net profit reached VND 212.8bn as revenue climbed to VND 11.67tn.FRT
Q1 2025 - H1 profit more than tripled as revenue advanced and pharmaceutical operations led segment results.FRT
Q2 2025